The results unveiled that a wide range of immune cell activation signatures is enriched in HRD-high cases of HER2-low EBC, which indicated that patients with BC with higher HRD might obtain a more enhanced response to therapies targeting these checkpoints. This evidence concerns the gene ERBB2 and breast cancer.